Ticker Hub
GYRE — AI Analysis & Sentiment
4 recent AI-generated analyses for GYRE. Sentiment and confidence insights updated continuously.
Kaskela Law LLC Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Long-Term GYRE Shareholders to Contact the Firm
Kaskela Law's investigation into Gyre Therapeutics for potential securities violations creates a significant legal overhang. Given the company's hi...
May 28, 2026Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
Gyre Therapeutics achieved a key regulatory milestone with NMPA acceptance of its F351 NDA, significantly advancing its lead drug candidate towards...
May 12, 2026Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment
NMPA's priority review for Hydronidone (F351) in China marks a significant de-risking event, accelerating the drug's path to market and providing s...
Mar 17, 2026Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Gyre Therapeutics' Q4 and FY2025 results revealed a concerning 2026 revenue guidance reduction and negative free cash flow, alongside a dilutive $3...
Mar 12, 2026